ARRIVENT BIOPHARMA INC (AVBP)
Health Care · Oncology - targeted therapeutics and antibody-drug conjugates · NASDAQ
Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung cancer with uncommon mutations, toward pivotal Phase 3 approval.
What ARRIVENT BIOPHARMA INC does
Arrivent Biopharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of differentiated medicines for cancer treatment. The company's lead product candidate is firmonertinib, an EGFR mutant-selective tyrosine kinase inhibitor being evaluated in pivotal Phase 3 trials for non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations, including exon 20 insertion and PACC mutations. Additionally, Arrivent is advancing a pipeline of next-generation antibody-drug conjugates, including ARR-217.
Themes: ["oncology / cancer immunotherapy","non-small cell lung cancer (NSCLC)","EGFR-mutant targeted therapy","antibody-drug conjugates (ADCs)","Phase 3 clinical development"]
Fundamentals
- Price$33.67 as of 2026-07-09 close
- Market cap$1.6B as of 2026-07-10
- 1-year return+64.3% as of 2026-07-09 close
- ROE-49.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.39 as of 2026-07-10
Key risks (from latest filing)
["Dependence on successful pivotal Phase 3 clinical trial results for firmonertinib; topline data from FURVENT trial expected mid-2026, with no guarantee of positive outcomes or FDA approval","Limited stage of development—all product candidates are pre-commercialization clinical assets with significant regulatory and clinical execution risk","Substantial operating losses and cash burn; the company reported $43.3 million net loss in Q1 2026 and accumulated deficit of $447.9 million as of March 31, 2026, with dependence on continued capital raising"]
Competitors & peers
- AstraZeneca (AZNA)
- Eli Lilly (LLY)
- Genmab (GMAB)
- Exelixis (EXEL)
- Amgen (AMGN)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.